US EditionPublished • loading... • Updated
Poolbeg Pharma (AIM: POLB) POLB 001 Phase 2a Trial Update
Summary by Share Talk
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Poolbeg Pharma plc - ACT appointed for POLB 001 Phase 2a Trial and supply of approved bispecific antibody drug secured at no cost - Optimum Strategic Communications
Trial to take place at The Christie NHS Foundation Trust and other leading UK specialist cancer centres 25 September 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that the Company has signed an agreement for a specialist blood cancer trials organisation, Accelerating Clinical Trials Limited (“ACT”), to […] The …
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
